Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?

Literature DB >> 15503000

Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?

Vibhav Malviya¹, Harbans Singh, U S Dwivedi, P B Singh.

Abstract

The aim of this study was to find the correlation between serum p53 and carcinoma of the bladder and to investigate whether serum p53 protein can be used as a tumor marker for p53 gene alteration. The study included patients with carcinoma of the bladder and controls. Serum p53 protein estimation was done with an ELISA kit. There were 23 patients with superficial and 17 with invasive carcinoma. The median serum p53 was 31.5 U/ml in superficial and 41 U/ml in invasive cancer. This was significantly higher than the mean value (16.4 U/ml) of controls. Serum p53 rises in patients with carcinoma of the bladder and correlates with the grade of the disease . It can therefore be used as a tumor marker for bladder cancer.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2004 PMID： 15503000 DOI： 10.1007/s00240-004-0415-9

Source DB: PubMed Journal: Urol Res ISSN： 0300-5623

15 in total

1. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

Authors: H Suwa; G Ohshio; N Okada; Z Wang; M Fukumoto; T Imamura; M Imamura
Journal: Gut Date: 1997-05 Impact factor: 23.059

2. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.

Authors: Ming-Lan Lu; Friedrik Wikman; Torben F Orntoft; Elizabeth Charytonowicz; Farhang Rabbani; Zuofeng Zhang; Guido Dalbagni; Kamal S Pohar; Guopei Yu; Carlos Cordon-Cardo
Journal: Clin Cancer Res Date: 2002-01 Impact factor: 12.531

3. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

Authors: C A Finlay; P W Hinds; T H Tan; D Eliyahu; M Oren; A J Levine
Journal: Mol Cell Biol Date: 1988-02 Impact factor: 4.272

4. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.

Authors: Regine Dahse; Michael Utting; Wolfram Werner; Bettina Schimmel; Uwe Claussen; Kerstin Junker
Journal: Int J Oncol Date: 2002-01 Impact factor: 5.650

5. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.

Authors: M G Friedrich; S Riethdorf; A Erbersdobler; C Tiemer; H Schwaibold; J K Sölter; E Huland; L Riethdorf; S Conrad; P G Hammerer; H Huland
Journal: Eur Urol Date: 2001-02 Impact factor: 20.096

6. Levels of p53 antigen in the serum of nonsmall cell lung-cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement.

Authors: G Fontanini; L Fiore; D Bigini; S Vignati; S Calvo; A Mussi; M Lucchi; C Angeletti; G Merlo; F Basolo
Journal: Int J Oncol Date: 1994-09 Impact factor: 5.650

7. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

Authors: B J Schmitz-Dräger; P J Goebell; T Ebert; Y Fradet
Journal: Eur Urol Date: 2000-12 Impact factor: 20.096

8. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy.

Authors: S Jahnson; B Risberg; M G Karlsson; G Westman; R Bergström; J Pedersen
Journal: Eur Urol Date: 1995 Impact factor: 20.096

Serum p53 and bladder cancer: can serum p53 be used as a tumor marker?

1. Clinical significance of serum p53 antigen in patients with pancreatic carcinomas.

2. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.

3. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.

4. TP53 alterations as a potential diagnostic marker in superficial bladder carcinoma and in patients serum, plasma and urine samples.

5. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder.

6. Levels of p53 antigen in the serum of nonsmall cell lung-cancer patients correlate with positive p53 immunohistochemistry on tumor sections, tumor necrosis and nodal involvement.

7. p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists?

8. p53 and Rb immunostaining in locally advanced bladder cancer: relation to prognostic variables and predictive value for the local response to radical radiotherapy.

9. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon.

10. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value.

1. [Molecular markers in the diagnostics and therapy of urothelial cancer].

2. SERS-based nanobiosensing for ultrasensitive detection of the p53 tumor suppressor.